Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.

Abstract:

:Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cases of CML in late CP, which were switched to imatinib while in CCR after interferon alpha (IFN alpha) and reached complete and stable molecular remission with intermittent drug administration at 400mg/every 20 days/month.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Breccia M,Cannella L,Stefanizzi C,Santopietro M,De Cuia R,Diverio D,Alimena G

doi

10.1016/j.leukres.2008.10.024

subject

Has Abstract

pub_date

2009-05-01 00:00:00

pages

645-8

issue

5

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(08)00481-5

journal_volume

33

pub_type

杂志文章
  • Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.

    abstract::The tumor promoting agent TPA (phorbol ester; 1.6 X 10(-8)M) was used to induce the differentiation in vitro of B-chronic lymphocytic leukemia (B-CLL) cells from 14 untreated patients. The uninduced phenotype was SIg+, Mrbc+, RFT-1+, RFA-4-, FMC7-. After 72 h incubation with TPA, B-CLL cells became RFA-4+, FMC7+ and l...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(84)90005-5

    authors: Caligaris-Cappio F,Janossy G,Campana D,Chilosi M,Bergui L,Foà R,Delia D,Giubellino MC,Preda P,Gobbi M

    更新日期:1984-01-01 00:00:00

  • Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612).

    abstract::A retrospective cytogenetic study was performed to determine whether non-random chromosome aberrations were related to the outcome of marrow transplantation for advanced stage acute leukemia (AL) and chronic myelogenous leukemia (CML). The patients were registered on SWOG-8612, a randomized comparison of busulphan and...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/0145-2126(94)00162-4

    authors: Slovak ML,Kopecky KJ,Wolman SR,Henslee-Downey JP,Appelbaum FR,Forman SJ,Blume KG

    更新日期:1995-06-01 00:00:00

  • Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.

    abstract::The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis has been used to predict survival in diffuse large B-cell lymphoma (DLBCL) patients, but its prognostic significance with respect to different cell-of-origin (COO) subtypes remains unknown. We retrospectively analyzed 168 de novo DLBCL patients in th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2014.03.013

    authors: Wei X,Huang F,Wei Y,Jing H,Xie M,Hao X,Feng R

    更新日期:2014-06-01 00:00:00

  • Expression of IL-18 and its receptor in human leukemia cells.

    abstract::The importance of IL-18, although clearly established in solid tumors, has not been fully elucidated in human hematopoietic neoplasms. Here we examined the mRNA and protein for IL-18 in eight human hematopoietic cell lines representing different lineages and neoplasms including leukemia, lymphoma and others. Our resul...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(03)00005-5

    authors: Zhang B,Ma XT,Zheng GG,Li G,Rao Q,Wu KF

    更新日期:2003-09-01 00:00:00

  • Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

    abstract::Fusion tyrosine kinases (FTKs) such as BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGF beta R and NPM/ALK arise from reciprocal chromosomal translocations and cause acute and chronic myelogenous leukemias and non-Hodgkin's lymphoma. Murine hematopoietic growth factor dependent BaF3 cells and cells transformed by FTK (BaF3-FTK) w...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00163-7

    authors: Hoser G,Majsterek I,Romana DL,Slupianek A,Blasiak J,Skorski T

    更新日期:2003-03-01 00:00:00

  • Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling.

    abstract::Chemotherapy resistance has been considered as a major problem for multiple myeloma (MM) treatment and bone marrow microenvironment plays a crucial role in the MM progression and chemoresistance. Recent studies reported that bone marrow mesenchymal stem cells derived from MM patients (MM-MSCs) revealed various charact...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.07.002

    authors: Yang H,Zheng Y,Zhang Y,Cao Z,Jiang Y

    更新日期:2017-09-01 00:00:00

  • Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.

    abstract::We conducted a retrospective analysis to investigate the clinical outcome of combined-modality therapy using multiagent chemotherapy and involved-field radiotherapy in treatment of children with Hodgkin's lymphoma. Fifty eight cases with newly diagnosed Hodgkin's lymphoma were analyzed. The median follow-up duration w...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.06.012

    authors: Ali A,Sayed H,Farrag A,El-Sayed M

    更新日期:2010-11-01 00:00:00

  • The venom of the spider Macrothele raveni induces apoptosis in the myelogenous leukemia K562 cell line.

    abstract::Spider venoms are a rich source of bioactive compounds with therapeutic potential. In traditional Chinese medicine, spiders and spider venoms have been used in the treatment of various ailments. In the present study, the venom of the spider Macrothele raveni potently suppressed cell growth in the myelogenous leukemia ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.02.025

    authors: Liu Z,Zhao Y,Li J,Xu S,Liu C,Zhu Y,Liang S

    更新日期:2012-08-01 00:00:00

  • In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.

    abstract::Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p<0.001) and do...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.06.012

    authors: Lönnerholm G,Thörn I,Sundström C,Frost BM,Abrahamsson J,Behrendtz M,Heldrup J,Jacobsson S,Li A,Olofsson T,Porwit A,Söderhäll S,Larsson R,Forestier E

    更新日期:2009-01-01 00:00:00

  • Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

    abstract::A novel bone biopsy technique was used to generate a robust stromal cell system to study how stroma modulates CLL B-cell apoptosis and how the leukemic cell-stromal interaction influences secretion of vascular factors. Marrow stromal elements (MSE) rescued CLL B-cells from both spontaneous and drug induced apoptosis, ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.11.024

    authors: Kay NE,Shanafelt TD,Strege AK,Lee YK,Bone ND,Raza A

    更新日期:2007-07-01 00:00:00

  • YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.

    abstract::Adult T-cell leukemia (ATL) is an aggressive malignancy of peripheral T cells infected with human T-cell leukemia virus type 1 (HTLV-1). The prognosis of patients with aggressive ATL remains poor because ATL cells acquire resistance to conventional cytotoxic agents. Therefore, development of novel agents is urgently n...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.10.012

    authors: Sasaki R,Ito S,Asahi M,Ishida Y

    更新日期:2015-12-01 00:00:00

  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

    abstract::Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2005.10.025

    authors: Moore J,Seiter K,Kolitz J,Stock W,Giles F,Kalaycio M,Zenk D,Marcucci G

    更新日期:2006-07-01 00:00:00

  • Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.

    abstract::This 5-year, prospective registry enrolled 600 lower-risk MDS patients (pts) with transfusional iron overload. Clinical outcomes were compared between chelated and nonchelated pts. At baseline, cardiovascular comorbidities were more common in non-chelated pts, and MDS therapy was more common in chelated pts. At 24 mon...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2013.11.004

    authors: Lyons RM,Marek BJ,Paley C,Esposito J,Garbo L,DiBella N,Garcia-Manero G

    更新日期:2014-02-01 00:00:00

  • Survival in acute myeloblastic leukemia is not prolonged by remission maintenance or early reinduction chemotherapy. The Toronto Leukemia Study Group.

    abstract::A role for post-induction chemotherapy for adult patients with acute myeloblastic leukemia in remission has not been established. We have studied 125 patients with acute myeloblastic leukemia in complete remission to determine the effect on survival of remission maintenance therapy and of early reinduction therapy giv...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0145-2126(88)90136-1

    authors:

    更新日期:1988-01-01 00:00:00

  • An autologous tumor vaccine for CLL.

    abstract::Chronic Lymphocytic Leukemia B cells (CLL) are malignant cells which retain at least some functions of normal B cells. Paramount amongst the latter is that when such cells are appropriately stimulated, they are able to present antigens, including any potential tumor antigens, making them excellent choices as a candida...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2018.03.002

    authors: Zhu F,Khatri I,Spaner D,Gorczynski RM

    更新日期:2018-05-01 00:00:00

  • Balance of NF-kappaB and p38 MAPK is a determinant of radiosensitivity of the AML-2 and its doxorubicin-resistant cell lines.

    abstract::This study investigated radioresistance mechanisms in the doxorubicin-resistant acute myelogenous leukemia (AML)-2/DX100. AML-2/DX100 also showed resistance to radiation. AML-2/DX100 characterized by down-regulated catalase expression was supersensitive to exogenous hydrogen peroxide whereas they increased defense mec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.11.006

    authors: Choi CH,Xu H,Bark H,Lee TB,Yun J,Kang SI,Oh YK

    更新日期:2007-09-01 00:00:00

  • BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

    abstract::The Bcl-2 protein inhibits apoptosis (programmed cell death) of hematopoietic stem cells induced by a variety of noxious stimuli, thus mediating chemoresistance and decreasing chemosensitivity. Higher Bcl-2 expression correlates to an adverse outcome following therapy for acute myeloid leukemia (AML). The current stud...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.05.009

    authors: Moon JH,Sohn SK,Lee MH,Jang JH,Kim K,Jung CW,Kim DH

    更新日期:2010-02-01 00:00:00

  • Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire.

    abstract::This paper reports the results of a case control study of non-Hodgkin's lymphoma in the Yorkshire Health Region. In all, 437 cases and 724 controls were interviewed. Risk factors associated with past skin conditions, family history of cancer and infectious mononucleosis, aspects of social life and contact with wood du...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)80012-x

    authors: Cartwright RA,McKinney PA,O'Brien C,Richards ID,Roberts B,Lauder I,Darwin CM,Bernard SM,Bird CC

    更新日期:1988-01-01 00:00:00

  • Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

    abstract::Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.03.015

    authors: Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

    更新日期:2015-07-01 00:00:00

  • PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.

    abstract::Based on Bcl-X(L) overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-kappaB, PDTC, enabled TRAIL to a...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.09.025

    authors: Nuutinen U,Simelius N,Ropponen A,Eeva J,Mättö M,Eray M,Pellinen R,Wahlfors J,Pelkonen J

    更新日期:2009-06-01 00:00:00

  • KN-62 analogues as potent differentiating agents of HL-60 cells.

    abstract::KN-62, an inhibitor of the calmodulin-dependent protein kinases (CaMKs), enhances the terminal differentiation of retinoic acid sensitive human myeloid leukemia cell lines. In an effort to identify additional CaMK inhibitors that exhibit more potent activity in triggering leukemia cell differentiation, we synthesized ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.07.022

    authors: Schuler AD,Si J,Mueller L,Simon JA,Collins SJ

    更新日期:2007-05-01 00:00:00

  • The correlation of adenosine deaminase and purine nucleoside phosphorylase activities in human lymphocytes subpopulations and in various lymphoid malignancies.

    abstract::Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) were measured in normal human and in malignant lymphoid cells. Thymocytes had high ADA activity (21.2 +/- 6.8 10(3) nM/h/mg) and low PNP activity (1.2 +/- 0.6), whereas T peripheral blood lymphocytes (PBL) had low ADA activity (1.20 +/- 0.22) and high...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90027-3

    authors: Demeocq F,Viallard JL,Boumsell L,Richard Y,Chassagne J,Plagne R,Lemerle J,Bernard A

    更新日期:1982-01-01 00:00:00

  • HIC gene, a candidate suppressor gene within a minimal region of loss at 7q31.1 in myeloid neoplasms.

    abstract::We studied monosomy and deletions of chromosome 7 in 170 patients with myeloid disorders and we identified a minimal region of loss in 7q31.1 spanning between the D7S2554 and D7S2460 markers. The closest gene to our most deleted microsatellite, D7S2554, is the human I-mfa domain containing (HIC) gene, alias MyoD famil...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.09.007

    authors: Cigognini D,Corneo G,Fermo E,Zanella A,Tripputi P

    更新日期:2007-04-01 00:00:00

  • Expression of the non-T ALL-associated p24 antigen on leukaemic blasts from patients with ANLL.

    abstract::Leukaemic cells from the peripheral blood of 90 patients with acute leukaemia (54 non-lymphocytic (ANLL) 36 lymphocytic (ALL)) have been examined for the presence of the platelet/ALL-associated p24 membrane antigen by indirect immunofluorescence and flow cytometry using monoclonal antibody FMC8. Cells from 28 of the A...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(87)90109-3

    authors: Ashman LK,White D,Zola H,Dart GW

    更新日期:1987-01-01 00:00:00

  • Aspiration biopsy-nucleic acid diagnosis of thyroid malignant lymphoma by vectorette PCR: experience of eight cases.

    abstract::The usefulness of a new method to detect B-cell monoclonality named VR, which is a combination of the digestion with restriction enzymes and vectorette PCR, in aspiration biopsy-nucleic acid diagnosis (ABND) of thyroid malignant lymphoma was investigated. ABND was performed in 12 patients in whom malignant lymphoma wa...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.03.019

    authors: Takano T,Asahi S,Matsuzuka F,Hidaka Y,Yoshida H,Miyauchi A

    更新日期:2008-01-01 00:00:00

  • Reciprocal alterations of GMP reductase and IMP dehydrogenase activities during differentiation in HL-60 leukemia cells.

    abstract::The study was undertaken to elucidate the regulatory roles of GMP reductase (GMPR) and IMP dehydrogenase (IMPDH) on purine interconversion during differentiation. Treatment of HL-60 cells with retinoic acid (1 microM) induced granulocytic differentiation which was accompanied with a 2.4-fold increase in GMPR and 55% d...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(92)90002-o

    authors: Nakamura H,Natsumeda Y,Nagai M,Takahara J,Irino S,Weber G

    更新日期:1992-06-01 00:00:00

  • Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.

    abstract::Plasma levels of beta-2 microglobulin (beta2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.02.013

    authors: Albitar M,Vose JM,Johnson MM,Do KA,Day A,Jilani I,Kantarjian H,Keating M,O'Brien SM,Verstovsek S,Armitage JO,Giles FJ

    更新日期:2007-02-01 00:00:00

  • Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.

    abstract::Aberrant expression of tumor suppressor genes WT 1, RB 1, p53, homozygous deletion of p16 gene and their relationship with expression of oncogenes BCR-ABL, TEL-AML 1, MLL-AF 4, E2A-PBX 1, SIL-TAL 1 were determined in bone marrow samples of children with de novo B-lineage (n=170) and T-lineage (n=25) acute lymphoblasti...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.04.006

    authors: Kustanovich AM,Savitskaja TV,Bydanov OI,Belevtsev MV,Potapnev MP

    更新日期:2005-11-01 00:00:00

  • Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

    abstract::Higher-risk myelodysplastic syndromes (MDS) are rarely curable and have a poor prognosis. We investigated the accuracy of physicians' perception of patients' health status and the patients' preferences for involvement in treatment decisions. We examined 280 newly diagnosed higher-risk elderly MDS patients paired with ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.05.012

    authors: Caocci G,Voso MT,Angelucci E,Stauder R,Cottone F,Abel G,Nguyen K,Platzbecker U,Beyne-Rauzy O,Gaidano G,Invernizzi R,Molica S,Criscuolo M,Breccia M,Lübbert M,Sanpaolo G,Buccisano F,Ricco A,Palumbo GA,Niscola P,Zhan

    更新日期:2015-08-01 00:00:00

  • Caspase-8 dependent apoptosis induction in malignant myeloid cells by TLR stimulation in the presence of IFN-alpha.

    abstract::Pro-apoptotic signalling upon toll-like receptor (TLR) stimulation in myeloid cells is normally antagonized by the simultaneous activation of anti-apoptotic pathways. We have previously reported that IFN-alpha can sensitize human monocytes to apoptosis induction by lipopolysaccharide (LPS). Based on these results we i...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.05.001

    authors: Lehner M,Bailo M,Stachel D,Roesler W,Parolini O,Holter W

    更新日期:2007-12-01 00:00:00